Mathematical modeling of endemic cholera transmission

Dennis L. Chao

Institute for Disease Modeling; Bill & Melinda Gates Foundation; 500 5th Ave N; Seattle, Washington 98109; USA

E-mail: dennisc@idmod.org

Footnote page

Potential conflicts of interest. The author declares no conflicts of interest. The author has submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Financial support. The author is an employee of The Bill & Melinda Gates Foundation. No funds, grants, or other support was received for this work.

Previous presentation. A version of the material in this manuscript was presented at the 15th Asian Conference on Diarrhoeal Disease and Nutrition.

Disclaimer. The findings and conclusions contained within are those of the author and do not necessarily reflect the official positions or policies of the Bill & Melinda Gates Foundation.
Abstract:

Mathematical modeling can be used to project the impact of mass vaccination on cholera transmission. Here, we discuss two examples for which indirect protection from mass vaccination needs to be considered. In the first, we show that non-vaccinees can be protected by mass vaccination campaigns. This additional benefit of indirect protection improves the cost-effectiveness of mass vaccination. In the second, we model the use of mass vaccination to eliminate cholera. In this case, a high population level of immunity, including contributions from infection and vaccination, is required to reach the “herd immunity” threshold needed to stop transmission and achieve elimination.

Key words: Mathematical modeling, cholera, oral cholera vaccine
Background

Oral cholera vaccine (OCV) can be used to combat epidemic and endemic cholera [1]. In some ways, the quantitative support for interventions against endemic cholera, such as vaccination, improved sanitation, and education campaigns, is more straightforward than in non-endemic regions, where outbreaks are sporadic and less predictable. If outbreaks occur regularly, then interventions focus on endemic “hot spots” and targeted by age or other sub-population if appropriate. But even with relatively predictable outbreaks, estimating the impact of interventions can be difficult. Dynamic modeling, which uses mathematical equations or computer models to simulate disease spread, can capture some of the complicated effects of interventions. Here, we illustrate the use of dynamic modeling to help understand the impact of mass vaccination on endemic cholera transmission in two different settings: Bangladesh and Haiti.

Dynamic modeling for improving cost effectiveness estimates

OCV provides adults good protection for several years, with lower efficacy among young children [2], [3]. However, because young children have generally been found to have higher incidence than adults in endemic settings, it is worth considering prioritizing them for vaccination [4]. To estimate the effectiveness of mass vaccination with OCV, one could start with a simple calculation, where the reduction in cholera cases is simply proportional to vaccine coverage and vaccine efficacy [5]. This could help weigh the merits of prioritizing children (lower efficacy but higher incidence) or adults (higher efficacy but lower incidence) when resources are scarce. However, this calculation ignores the potentially substantial indirect protection from mass vaccination.

In a re-analysis of an individually-randomized OCV trial, cholera incidence was found to be lower among placebo recipients if nearby OCV coverage was high [6]. In other words, non-vaccinees benefited from vaccinated neighbors. This makes intuitive sense – if disease incidence or risk is reduced among your likely contacts, then you are at less risk of infection as well [7]. Figure 1 illustrates the potential magnitude of indirect protection from vaccination. Direct protection would only protect those who are vaccinated. The number of cholera cases averted by direct protection is proportional to vaccination coverage, so cholera incidence would only be reduced by about 30-40% even with an impossibly high 100% coverage. But the field trial revealed higher-than-expected protection in areas with high coverage [6], and a dynamic model was later fit to these data to provide a mechanistic interpretation [8]. At sufficiently high levels of vaccination, at which infected individuals infect on average less than one other, disease transmission basically stops. This phenomenon has been called herd protection or community immunity [9]. The potentially huge gains from indirect protection became a key part of several cost-effectiveness analyses of OCV [10].
Figure 1: Observed and modeled protection from mass cholera vaccination in Bangladesh. “Direct protection” assumes that vaccine efficacy is 65% and that there are no indirect protection from vaccination. “Observed” points are based on the field trial described in [11] and [6]. “Overall protection” is derived using the model described in [8]. This figure was adapted from [5].

We used dynamic models of cholera transmission to simulate the vaccination of three age groups in Dhaka, Bangladesh: 1 to 4 years old, 1 to 14, and everyone one year old and older [12], [13]. Briefly, these models used systems of ordinary differential equations (ODEs) to simulate the spread of cholera from infected people or the environment to susceptible people. Transmission from the environment peaked twice each year to capture the seasonal cholera outbreaks in Bangladesh [14]. As expected, vaccinating everyone prevented the most cases in the models, but vaccinating 1 to 14-year-olds was most cost effective by preventing the most cases per vaccination. Limiting vaccination to children under 5 years old was less effective because vaccine efficacy is lower among young children and because vaccinating a small portion of the population does not substantially reduce overall cholera circulation. Increasing the target to include children up to 14 years old not only directly protected this larger segment of the population, but it also partially protected the rest of the population by reducing cholera transmission from children. In other words, vaccinating children can protect adults.

Because we were evaluating the potential benefit of recurring mass vaccination campaigns, we had to simulate the dynamics of cholera over several years. We assumed that children who were vaccinated before they were 5 years old would have less protection than those vaccinated when they were older, based on observations from [3]. It was therefore important to re-vaccinate the youngest children when they got older. The high population coverage that conferred indirect protection was hard to maintain. In addition to vital dynamics (i.e., births and deaths) steadily eroding population-level coverage, the high-risk populations living in urban slums had high turnover, making it difficult to maintain sufficient vaccine coverage levels without regular vaccination campaigns to reach newly-arrived unvaccinated adults.

**Dynamic modeling of cholera elimination**

Cholera was introduced to Haiti in late 2010, and hundreds of thousands of cases were reported over the following two years [15]. After the first massive waves, cholera appeared to persist at lower levels, with more outbreaks during the rainy season. Unlike Bangladesh, where V. cholerae is an autochthonous part of the Bay of Bengal [16], cholera has not been a persistent presence in the Americas. With no obvious natural reservoir, interrupting transmission among humans could eliminate cholera from Haiti. Interrupting transmission would not require vaccinating every resident of Haiti – vaccine just needs to reach enough people to prevent chains of transmission from persisting throughout the year. Dynamic modeling could be used to understand how interventions could stop cholera transmission in the context of seasonality and waning...
immunity. Several mass vaccination scenarios in Haiti were modeled by four independent modeling teams, and the results were reported in [17]. Here, we describe one of those models.

We had adapted a model that had originally been developed to understand the potential impact of mass vaccination soon after cholera introduction [18]. Unlike the model for Bangladesh described earlier, the model for Haiti is agent-based, meaning each person in the country’s population is represented explicitly. One reason for this computationally expensive modeling choice was to allow us to track the number of cholera cases instead of the proportion of the population that is infected. By tracking the exact number of cases, we can define the “elimination” of cholera to be when the last simulated case of cholera occurs. Simulated individuals reside in an environment that captures a few major geographic features of Haiti, such as roads and proximity to rivers. Individuals living near rivers are exposed to environmental *V. cholerae* from communities living upstream, and individuals living near roads could encounter and be infected by people who live along the same roads. Susceptible children and adults have the same level of exposure to cholera, but adults are more likely to be immune from prior infection. The updated model added waning immunity after cholera infection or vaccination, since we were simulating cholera transmission over several years [17]. We also added seasonality. Cholera transmission appears to be rainfall-driven in Haiti, so transmission was higher during Haiti’s rainy season.

Our model found that cholera infected millions of people in Haiti over the first year, which drove down the number of people susceptible to cholera (Figure 2). The high level of population-level immunity from these massive outbreaks blunted outbreaks in subsequent years. This population-level immunity is steadily diminished as (fully susceptible) people are born and immunity wanes among those who had been infected, so the number of susceptibles climb. When the number of susceptible people is sufficiently high and cholera transmission is facilitated by the annual rainy season, outbreaks occur and drive the number of susceptibles back down. Because cholera appears to be less transmissible in the dry season in Haiti, there is a chance that the number of cases could drop to zero during a dry season and cholera would disappear from the country [19]. We deliberately calibrated our model to ensure cholera transmission from 2010 to at least 2018 (when the model was developed), which might make the model pessimistic about the possibility of elimination. At the time of writing, the last reported case of cholera in Haiti was in 2019 [20], and it is possible that cholera would or did spontaneously disappear from Haiti without additional interventions.

Figure 2: Modeling the dynamics of cholera in Haiti. The panel shows the number of cholera-susceptible people in the simulated population from one stochastic run of a model. Millions of people were infected when cholera was first introduced in 2010, causing a steep drop in the number of residents susceptible to cholera. After the initial massive outbreaks, our model predicts that the number of susceptibles had annual cycles, with the net number of susceptible individuals increasing due to births and waning immunity during the dry seasons and decreasing when rainy-season outbreaks depleted susceptibles. We simulated different mass OCV vaccination strategies starting in January 2019.
Driving the number of people susceptible to cholera down below a critical threshold across the country should result in elimination. We found that a rapid mass vaccination campaign covering the whole country within two years would have the best chance of eliminating cholera. A slower rollout that spanned 5 years was less effective because it was not fast enough to counter waning vaccine efficacy and vital dynamics—the first department to be vaccinated was able to support cholera transmission by the time the last department was reached. Vaccinating only the most cholera-affected departments was not likely to achieve elimination because cholera could persist in the unvaccinated regions and re-invade the vaccinated departments as immunity waned.

Discussion

Dynamic models can be used to project the effectiveness of mass vaccination including indirect or herd protection. For cholera vaccination, where direct protection is moderate but high coverage results in good population-level protection, modeling may be necessary when considering mass cholera vaccination to mitigate or eliminate cholera. We used a dynamic model to show the impact of recurring mass vaccination campaigns in Dhaka over the course of several years, and it was necessary to incorporate vital dynamics and migration, which erode population-level vaccine coverage. We used a different model to simulate the rollout of vaccine in Haiti, which could disrupt the equilibrium between rising susceptibility from waning immunity and vital dynamics and the regular outbreaks that maintain cholera endemicity. Dynamic models were needed to capture the seasonally varying force of infection and a potential gradual rollout of vaccine across the country. It is more difficult to include the impact of non-pharmaceutical interventions, such as WASH and education campaigns, since it is hard to measure compliance and it could be sensitive to changes in implementation. Therefore, we assumed that mass vaccination reduced cholera transmission below “status quo” levels, which are determined by the effectiveness of other interventions that do not change over time in the model. Similar dynamic models can be used to simulate single outbreaks of epidemic cholera, though parameterization and model features could differ. For example, population dynamics and the seasonality of transmission may be more relevant to endemic cholera dynamics while changes in behavior due to WASH interventions could have larger effects on outbreaks in populations that are less familiar with cholera [21].

Dynamic models have been played an increasingly important role in public health decisions. Measles elimination seemed impossible until an effective vaccine was developed and models quantified the level of vaccination required to prevent transmission and re-introduction [22], [23]. Without modeling, it had seemed obvious to focus influenza vaccination efforts on the elderly, who are at higher risk of severe outcomes. But multiple modeling studies showed that vaccinating schoolchildren would also protect adults, making child vaccination a cost-effective strategy [24], [25], [26]. With growing availability of OCV, we believe that modeling will play a key role in planning cholera interventions.

Acknowledgments

The author would like to thank the organizers of the 15th Asian Conference on Diarrhoeal Disease and Nutrition. The author is employed by the Institute for Disease Modeling, a research group within the Bill & Melinda Gates Foundation. The views in this article are those of the author and do not necessarily represent the views or policies of the employer.
References

[1] World Health Organization. Cholera vaccines: WHO position paper - August 2017. Wkly Epidemiol Rec. 2017 Aug 25;92(34):477–98.

[2] Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2013 Dec;13(12):1050–6. doi:10.1016/S1473-3099(13)70273-1.

[3] Fong Y, Halloran ME, Park JK, Marks F, Clemens JD, Chao DL. Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial. BMC Infect Dis. 2018 Feb 20;18(1):84. doi:10.1186/s12879-018-2981-4.

[4] Deen JL, von Seidlein L, Sur D, Agtini M, Lucas MES, Lopez AL, et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis. 2008 Feb 20;2(2):e173.

[5] Troeger C, Sack DA, Chao DL. Evaluation of targeted mass cholera vaccination strategies in Bangladesh: A demonstration of a new cost-effectiveness calculator. Am J Trop Med Hyg. 2014 Dec 3;91(6):1181–9. doi:10.4269/ajtmh.14-0159.

[6] Ali M, Emch M, von Seidlein L, Yunus M, Sack DA, Rao M, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005 Jul 2-8;366(9479):44–9. doi:10.1016/S0140-6736(05)66550-6.
[7] Chao DL, Park JK, Marks F, Ochiai RL, Longini IM, Halloran ME. The contribution of neighbours to an individual’s risk of typhoid outcome. Epidemiol Infect. 2015 Dec;143(16):3520–7. doi:10.1017/S0950268815000692.

[8] Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med. 2007 Nov 27;4(11):e336. doi:10.1371/journal.pmed.0040336.

[9] Fine P, Eames K, Heymann DL. “Herd immunity”: a rough guide. Clin Infect Dis. 2011 Apr 1;52(7):911–6. doi:10.1093/cid/cir007.

[10] Teoh SL, Kotirum S, Hutubessy RCW, Chaiyakunapruk N. Global economic evaluation of oral cholera vaccine: A systematic review. Hum Vaccin Immunother. 2018 Feb 1;14(2):420–429. doi:10.1080/21645515.2017.1392422.

[11] Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990 Feb 3;335(8684):270–3.

[12] Dimitrov DT, Troeger C, Halloran ME, Longini IM, Chao DL. Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Negl Trop Dis. 2014 Dec;8(12):e3343. doi:10.1371/journal.pntd.0003343.

[13] Khan AI, Levin A, Chao DL, DeRoeck D, Dimitrov DT, Khan JAM, et al. The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis. PLoS Negl Trop Dis. 2018 Oct;12(10):e0006652. doi:10.1371/journal.pntd.0006652.
[14] Akanda AS, Jutla AS, Islam S. Dual peak cholera transmission in Bengal Delta: A hydroclimatological explanation. Geophysical Research Letters 2009;36:L19401. doi:10.1029/2009GL039312.

[15] Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, et al. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med. 2013 Feb 14;368(7):599–609. doi:10.1056/NEJMoa1204927.

[16] Huq A, West PA, Small EB, Huq MI, Colwell RR. Influence of water temperature, salinity, and pH on survival and growth of toxigenic Vibrio cholerae serovar O1 associated with live copepods in laboratory microcosms. Appl Environ Microbiol. 1984 Aug;48(2):420–4. doi:10.1128/AEM.48.2.420-424.1984.

[17] Lee EC, Chao DL, Lemaitre JC, Matrajt L, Pasetto D, Perez-Saez J, et al. Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. Lancet Glob Health. 2020 Aug;8(8):e1081–e1089. doi:10.1016/S2214-109X(20)30310-7.

[18] Chao DL, Halloran ME, Longini IM Jr. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7081–5. doi:10.1073/pnas.1102149108.

[19] Rebaudet S, Gazin P, Barrais R, Moore S, Rossignol E, Barthelemy N, et al. The dry season in Haiti: a window of opportunity to eliminate cholera. PLoS Curr. 2013;5. doi:10.1371/currents.outbreaks.2193a0ec4401d9526203af12e5024ddc.
[20] Pan American Health Organization. Haiti reaches one-year free of Cholera. January 2020. Available at: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=15684.

[21] Chao DL, Longini IM Jr., Morris JG Jr. Modeling cholera outbreaks. In G. Balakrish Nair and Yoshi Takeda, editors, Cholera Outbreaks. Current Topics in Microbiology and Immunology. Berlin: Springer-Verlag. vol 379:195–209. 2014.

[22] Sencer DJ, Dull HB, Langmuir AD. Epidemiologic basis for eradication of measles in 1967. Public Health Rep. 1967 Mar;82(3):253–6.

[23] Hinman AR, Orenstein WA, Papania MJ. Evolution of measles elimination strategies in the United States. J Infect Dis. 2004 May 1;189 Suppl 1:S17–22. doi:10.1086/377694.

[24] Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol. 2009 Sep 15;170(6):679–86. doi:10.1093/aje/kwp237.

[25] Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: An evidence synthesis and modelling study. PLoS Med. 2013 Oct;10(10):e1001527. doi:10.1371/journal.pmed.1001527.

[26] Baguelin M, Camacho A, Flasche S, Edmunds WJ. Extending the elderly- and risk-group programme of vaccination against seasonal influenza in England and Wales: a cost-effectiveness study. BMC Med. 2015 Oct 13;13:236. doi:10.1186/s12916-015-0452-y.
Figure 1

Mass vaccination effectiveness

- % cases averted vs. Vaccination coverage
- Observed (field trial)
- Overall protection (dynamic model projection)
- Direct protection (coverage * efficacy)
Figure 2

Susceptibles in the model

- First waves infect millions
- Births and waning immunity
- Thousands infected each rainy season
- Mass vaccination could rapidly reduce susceptibles and stop transmission

Number susceptible

2011 2013 2015 2017 2019 2021